ArticleCurrent drug targets2026
Cardioprotective Potential of
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiovascular diseases (CVDs) remain a major global health threat, accounting for a significant proportion of deaths worldwide. Doxorubicin (DOX) and Isoproterenol (ISO) are known to induce cardiotoxicity primarily through the generation of reactive oxygen species (ROS).
methodsDrug-likeness analysis of selected phytochemicals was performed using SwissTargetPrediction and SuperPred 3.0. Genes associated with DOX-induced cardiotoxicity were curated from GeneCards, OMIM (Online Mendelian Inheritance in Man), and DisGeNet. Molecular docking was performed to evaluate potential interactions with TOP2A, HIF1A, ABCB1, NOS3, PIK3R1, SRC, ABL1, and NR3C2. An in vivo cardiotoxicity model using DOX and ISO was employed to assess the cardioprotective effects of ethanolic extracts of Hedyotis corymbosa (EEHC). Wistar rats of either sex, weighing 200-220 g, were used in the study.
resultsDocking scores of Corycavidine against hub genes ranged from -6.66 kcal/mol to -1.26 kcal/mol, while MM-GBSA binding energies ranged from -50.22 kcal/mol to -8.28 kcal/mol, with the strongest binding observed for ABL1 (-50.22 kcal/mol). The NBE (cumulative ΔG_Coul and ΔG_vdW) was highest for NOS3 (-87.46 kcal/mol). EEHC administration significantly decreased CKMB, malondialdehyde, and glutathione levels, while HDL, catalase, and superoxide dismutase levels were markedly increased, accompanied by reductions in total blood cholesterol and triglyceride levels. DISCUSSION: DOX and ISO treatment resulted in myocardial wall thickening and lipoprotein accumulation, suggesting cardiac dysfunction. Computational docking and MM-GBSA analyses of 16 hub genes revealed a favorable binding profile of Corycavidine with several key proteins implicated in cardiovascular regulation and injury responses.
conclusionThese findings suggest that Corycavidine may serve as a multi-target cardioprotective agent, potentially modulating oxidative stress, inflammation, endothelial function, and cellular survival pathways.
Indexed as
Identifiers
41742616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.